


Tenascin-C

Structure of Tenascin-C

Tenascin-C is an extracellular matrix (ECM) glycoprotein that is composed of 210-400 kDa subunits consisting of four domains.

One subunit has a TA domain at the N-terminal end, then an epidermal growth factor-like sequence domain (EGF-like domain), a fibronectin type III (FN III) repeat domain, and a fibrinogen-like domain at the C-terminal end. There is an alternatively spliced domain in the FN III domain, and it generates some types of variants of Tenascin-C.

The subunits form a trimer by twisting at the N-terminal coiled domain and form a hexamer by a disulfide bond, in tissue.



Tenascin-C Antibodies

Code No.	Name		Volume	WB	IHC
10337	Anti-Human	Tenascin-C (EGF Like Domain) (4F10TT)	Mouse IgG MoAb	100ug	○ (※F/P, T) 1ug/mL 5ug/mL
10335	Anti-Human	Tenascin-C (Domain B) (4C8MS)	Mouse IgG MoAb	100ug	○ (※MW) 5ug/mL 5ug/mL

※ F/P, T: Can be Applied to Formalin Fixed Paraffin Embedded Tissue with Trypsin Pre-Treatment ※MW:MW Pre-treatment is necessary.


CHARACTERISTICS OF ANTIBODIES

Anti-Human Tenascin-C (EGF Like Domain) (4F10TT) Mouse IgG MoAb

This monoclonal antibody can specifically recognize EGF-like domain of TN-C, therefore the antibody can detect in all TN-C isoforms and cross-react with mouse, rat, chicken and rabbit.

Anti-Human Tenascin-C (Domain B) (4C8MS) Mouse IgG MoAb

This monoclonal antibody can specifically recognize domain B on FNIII repeat of TN-C and is useful for the study of organogenesis, tumor, cell injury caused by various types of stress, wound healing, regeneration and fibrosis. It cross-reacts with mouse and rat.



Human breast cancer (From Reference No.6)

Tenascin-C ELISA Kit

We have two types of Tenascin-C assay kit as follows. Each ELISA kit can specifically detect FN III-B or FN III-C domain in FN III repeat and can measure Tenascin-C high molecular weight variant (called as "Large") including the subunit in which FN III-B or FN III-C domain respectively.

While low molecular weight variants of Tenascin-C are present in normal tissue, it is said that high molecular variants of Tenascin-C is expressed in various diseased tissue including cancer.

Both ELISA kits doesn't measure total of every variants of Tenascin-C molecules.

Human Tenascin-C Large (FN III-C) Assay Kit - IBL

Code No.	Name	Incubation Time	Measurement Range	Test Sample	Volume
27751	Human Tenascin-C Large (FN III-C) Assay Kit - IBL	1st Incubation 37°C, 1hr 2nd Incubation 4°C, 30min	0.38~24 ng/mL	100 µL	96 Well
	Target Molecule	Coating Antibody	Labeled Antibody	Specimen	
	Human Tenascin-C high molecular weight variant including FN III-C domain	Anti-Human TN-C (19C4MS) Mouse MoAb. Specific to human FN III-C domain	Anti-Tenascin-C (4F10TT) Mouse MoAb. Reacts with EGF-like domain.	Human Serum, Heparin-Plasma (more than x5 dilution recommended) and Cell culture supernatant. (Plasma samples collected with EDTA, Sodium Citrate or NaF showed somewhat lower value.)	

Tenascin-C Large (FN III-B) Assay Kit - IBL

Code No.	Name	Incubation Time	Measurement Range	Test Sample	Volume
27767	Tenascin-C Large (FN III-B) Assay Kit - IBL	1st Incubation 37°C, 1hr 2nd Incubation 4°C, 30min	0.2~12.5 ng/mL	100 µL	96 Well
	Target Molecule	Coating Antibody	Labeled Antibody	Specimen	
	Human, Mouse, Rat Tenascin-C high molecular weight variant including FN III-B domain	Anti-TN-C (4C8MS) Mouse MoAb. Specific to FN III-B domain. Specific to FN III-B domain	Anti-Tenascin-C (4F10TT) Mouse MoAb. Reacts with EGF-like domain.	Human, Mouse, Rat Serum, EDTA-Plasma (x400 - x1,600 dilution recommended) and Cell culture supernatant (cross-reacts with FCS in medium).	

References:

1. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A; Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. *Circ J*. 2007 Mar;71(3):327-30.
2. Takeda A, Otani Y, Iseki H, Takeuchi H, Aikawa K, Tabuchi S, Shinozuka N, Saeki T, Okazaki Y, Koyama I. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer. *World J Surg*. 2007 Feb;31(2):388-94.
3. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. *J Am Coll Cardiol*. 2006 Jun 6;47(11):2319-25.
4. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. *J Am Coll Cardiol*. 2006 Jun 6; 47 (11):2319-25.
5. Tanaka H, El-Karef A, Kaito M, Kinoshita N, Fujita N, Horiike S, Watanabe S, Yoshida T, Adachi Y. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. *Liver Int*. 2006 Apr; 26 (3):311-8.
6. Hasegawa M, Sudo A, Nagakura T, Hirata H, Kinoshita N, Yoshida T, Uchida A. Tenascin-C levels in pseudosynovial fluid of loose hip prostheses. *Scand J Rheumatol*. 2005 Nov-Dec; 34 (6):464-8.
7. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, Kato Y, Nishikawa T, Toyozaki T, Hishida H, Yoshida T, Hiroe M. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. *J Pathol*. 2005 Mar; 205 (4):460-7.
8. Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N, Yoshida T, Uchida A. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. *J Rheumatol*. 2004 Oct; 31 (10):2021-6.
9. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. *Histol Histopathol*. 2004 Apr; 19 (2):517-25.
10. Tsunoda T, Inada H, Kalembeiyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression. *Am J Pathol*. 2003 Jun;162 (6):1857-67.
11. Sato M, Toyozaki T, Odaka K, Uehara T, Arano Y, Hasegawa H, Yoshida K, Imanaka-Yoshida K, Yoshida T, Hiroe M, Tadokoro H, Irie T, Tanada S, Komuro I. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. *Circulation*. 2002 Sep 10;106(11):1397-402.
12. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, Maki T, Nishikawa T, Sakakura T, Yoshida T. Tenascin-C is a useful marker for disease activity in myocarditis. *J Pathol*. 2002 Jul;197(3):388-94.
13. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. *Lab Invest*. 2001 Jul;81(7):1015-24.
14. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. *Dev Dyn*. 2000 Jun;218(2):235-59.
15. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. *Int J Cancer*. 1997 Sep 26;73(1):10-5.
16. Yoshida T, Matsumoto E, Hanamura N, Kalembeiyi I, Katsuta K, Ishihara A, Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. *J Pathol*. 1997 Aug;182(4):421-8.

Manufacturer :

Immuno-Biological Laboratories Co., Ltd.

5-1 Aramachi, Takasaki-shi, Gunma 370-0831, JAPAN

TEL: 027-310-8040

FAX: 027-310-8045

E-mail: do-ibl@ibl-japan.co.jp

URL: <http://www.ibl-japan.co.jp>

